Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Appointed COO
Employment agrmnt
TCR2 THERAPEUTICS INC. (TCRR) Create: Alert

All | News | Filings
Date FiledTypeDescription
05/11/2023 8-K Quarterly results
Docs: "TCR2 Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update CAMBRIDGE, Mass., May 11, 2023 - TCR2 Therapeutics Inc. , a clinical-stage cell therapy company with a pipeline of novel next-generation T cell therapies for patients suffering from solid tumors, today announced financial results for the first quarter ended March 31, 2023 and provided a corporate update. “We are pleased with our continued progress during the last quarter which included the announcement of the strategic combination of TCR2 with Adaptimmune. We believe that the integration of the two companies’ complimentary technology platforms and pipelines focused on treating solid tumors has the potential to fundamentally change the war on cancer,” said Garry Menzel, Ph.D., Presiden..."
03/23/2023 8-K Quarterly results
Docs: "TCR2 Therapeutics Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Corporate Update • TCR² and Adaptimmune announce strategic combination to create a preeminent cell therapy company focused on treating solid tumors • Following the expected Q2 2023 closing of the all-stock transaction, the combined company's cash runway is expected to extend into 2026 CAMBRIDGE, Mass., March 23, 2023- TCR2 Therapeutics Inc. , a clinical-stage cell therapy company with a pipeline of novel next-generation T cell therapies for patients suffering from solid tumors, today announced fourth quarter and full-year 2022 financial results and provided a corporate update. “Focus and specialization are critical in the cell therapy space. The strategic combination with Ad..."
11/08/2022 8-K Quarterly results
08/08/2022 8-K Quarterly results
05/12/2022 8-K Quarterly results
03/22/2022 8-K Quarterly results
Docs: "TCR2 Therapeutics Reports Fourth Quarter 2021 Financial Results and Provides Corporate Update CAMBRIDGE, Mass., March 22, 2022 - TCR2 Therapeutics Inc. , a clinical-stage cell therapy company with a pipeline of novel T cell therapies for cancer patients suffering from solid tumors, today announced financial results for the fourth quarter ended December 31, 2021 and provided a corporate update. "Consistent execution throughout the last year has positioned TCR2 for a series of important readouts as we accelerate our clinical progress in 2022," said Garry Menzel, Ph.D., President and Chief Executive Officer of TCR2 Therapeutics. "We were able to successfully conclude the dose escalation portion of our ongoing gavo-cel Phase 1/2 clinical trial with the identification of a RP2D and ..."
11/10/2021 8-K Quarterly results
Docs: "TCR2 Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Update"
08/05/2021 8-K Quarterly results
03/11/2021 8-K Quarterly results
11/12/2020 8-K Quarterly results
Docs: "Cash Position: TCR 2 ended the third quarter of 2020 with $246.7 million in cash, cash equivalents, and investments compared to $158.1 million as of December 31, 2019. Net cash used in operations was $10.8 million for the third quarter of 2020 compared to $10.1 million for third quarter of 2019. TCR 2 continues to project net cash use of $65-70 million for 2020. • R&D Expenses: Research and development expenses were $12.8 million for the third quarter of 2020 compared to $11.4 million for the third quarter of 2019. The increase in R&D expenses is primarily related to increase in headcount, activities related to the Phase 1/2 clinical trial of TC-210 and activities related to the Phase 1/2 clinical trial of TC-110. • G&A Expenses: General and administrative expense..."
08/12/2020 8-K Quarterly results
05/14/2020 8-K Quarterly results
Docs: "Cash Position: TCR 2 ended the first quarter of 2020 with $140.7 million in cash, cash equivalents, and investments compared to $158.1 million as of December 31, 2019. Net cash used in operations was $16.4 million for the first quarter of 2020 compared to $10.8 million for first quarter of 2019. TCR 2 projects net cash use of $60-70 million for 2020. • R&D Expenses: Research and development expenses were $12.0 million for the first quarter of 2020 compared to $7.9 million for the first quarter of 2019. The increase in R&D expenses is primarily related to increase in headcount, activities related to the Phase 1/2 clinical trial of TC-210 and activities related to the Phase 1/2 clinical trial of TC-110. • G&A Expenses: General and administrative expenses were $4.3 million for t..."
03/30/2020 8-K Quarterly results
Docs: "Cash Position: TCR 2 ended 2019 with $158.1 million in cash, cash equivalents, and investments compared to $123.2 million as of December 31, 2018. Net cash used in operations was $41.4 million for 2019 compared to $18.7 million for 2018. TCR 2 projects net cash use of $60-70 million for 2020. • R&D Expenses: Research and development expenses were $37.5 million for 2019 compared to $19.7 million for 2018. The increase in R&D expenses is primarily related to increase in headcount, activities related to the Phase 1/2 clinical trial of the Company’s lead solid tumor product candidate, TC-210, and activities related to the IND submission of the Company’s lead hematologic cancer product candidate, TC-110. • G&A Expenses: General and administrative expenses were $13.9 million for 20..."
11/12/2019 8-K Quarterly results
08/08/2019 8-K Quarterly results
05/13/2019 8-K Quarterly results
Docs: "TCR 2 Therapeutics Reports First Quarter 2019 Financial Results and Provides Corporate Update"
04/01/2019 8-K Quarterly results
Docs: "TCR 2 Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update"

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy